Sell-side Consensus on: Intuitive Surgical, Inc. (NASDAQ:ISRG), Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

For the current quarter, analysts are expecting Intuitive Surgical, Inc. (NASDAQ:ISRG) to report EPS of $3.97. This consensus estimate is provided by Zacks Research. After the period that ended on 2016-12-31, Intuitive Surgical, Inc. (NASDAQ:ISRG) reported an EPS actual of $5.3. The difference between the actual and estimate resulted in a surprise factor of 0.76%. The company is expected to release their next earnings report on or around 2017-04-18. Interested parties will be watching to see how company results compare to what the Street was projecting for the fiscal period.

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) have a current ABR or average broker rating of 1.91. This consensus recommendation is also provided by Zacks Research. The recommendation falls on a scale between 1 and 5. A broker rating of 1 would translate into a Strong Buy. A rating of 5 would indicate a Strong Sell recommendation. This consensus broker rating may help shed some light on how the sell-side is currently viewing company stock.

Covering analysts often provide target price projections for company shares. The current Zacks consensus target price on shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) is $761.363. The top analyst target is $840, and the lowest target is $600 on the stock. Because of the different techniques used to gauge a company target price, estimates may be quite different from one analyst to another.

In the most recent session, Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares have traded -0.45%. Following the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent review, the stock has been noted $-2.53 away from the 50-day moving average of $13.56 and $-6.76 away from the 200-day moving average of $17.79. From a different angle, the stock has been recently recorded -71.35% off of the 52-week high of 38.50 and +6.57% removed from the 52-week low of 10.35. 

Currently, Valeant Pharmaceuticals Interna has a price to earnings ratio of N/A. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio below one, it may be viewed as undervalued. If a company has a PEG Ratio above one, it may show that the company is overvalued. A PEG Ratio near one may be viewed as fair value. The stock currently has a PEG Ratio of 0.22.

Price Target Update

Analysts polled by Thomson Reuters have set a consensus target price of $17.34 on shares. Target prices may vary from one analyst to another due to the various ways they may proceed to calculate future price targets. This is a near-term estimation for the next 12-18 months.

Leave a Comment